• Association of Germiline BRCA Pathogenic Variants with Diminished..

    Survival with Cemiplimab in Recurrent Cervical Cancer

    Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial

    NItrogen-based bisphosphonate use ad ovarian cancer risk in women aged 50 years and older